These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

139 related items for PubMed ID: 27186284

  • 21. Tacrolimus therapy in adults with steroid- and cyclophosphamide-resistant nephrotic syndrome and normal or mildly reduced GFR.
    Li X, Li H, Ye H, Li Q, He X, Zhang X, Chen Y, Han F, He Q, Wang H, Chen J.
    Am J Kidney Dis; 2009 Jul; 54(1):51-8. PubMed ID: 19406543
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of entecavir for chronic HBV in HIV/HBV coinfected patients receiving lamivudine as part of antiretroviral therapy.
    Pessôa MG, Gazzard B, Huang AK, Brandão-Mello CE, Cassetti I, Mendes-Corrêa MC, Soriano V, Phiri P, Hall A, Brett-Smith H.
    AIDS; 2008 Sep 12; 22(14):1779-87. PubMed ID: 18753861
    [Abstract] [Full Text] [Related]

  • 23. Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: a randomized clinical trial.
    Huang H, Li X, Zhu J, Ye S, Zhang H, Wang W, Wu X, Peng J, Xu B, Lin Y, Cao Y, Li H, Lin S, Liu Q, Lin T.
    JAMA; 2014 Dec 17; 312(23):2521-30. PubMed ID: 25514302
    [Abstract] [Full Text] [Related]

  • 24. Tacrolimus monotherapy in membranous nephropathy: a randomized controlled trial.
    Praga M, Barrio V, Juárez GF, Luño J, Grupo Español de Estudio de la Nefropatía Membranosa.
    Kidney Int; 2007 May 17; 71(9):924-30. PubMed ID: 17377504
    [Abstract] [Full Text] [Related]

  • 25. Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection.
    de Man RA, Wolters LM, Nevens F, Chua D, Sherman M, Lai CL, Gadano A, Lee Y, Mazzotta F, Thomas N, DeHertogh D.
    Hepatology; 2001 Sep 17; 34(3):578-82. PubMed ID: 11526545
    [Abstract] [Full Text] [Related]

  • 26. Comparison of the efficacy of tenofovir and entecavir for the treatment of nucleos(t)ide-naive patients with chronic hepatitis B.
    Doğan ÜB, Kara B, Gümürdülü Y, Soylu A, Akin MS.
    Turk J Gastroenterol; 2012 Jun 17; 23(3):247-52. PubMed ID: 22798114
    [Abstract] [Full Text] [Related]

  • 27. Early hepatitis B virus DNA reduction in hepatitis B e antigen-positive patients with chronic hepatitis B: A randomized international study of entecavir versus adefovir.
    Leung N, Peng CY, Hann HW, Sollano J, Lao-Tan J, Hsu CW, Lesmana L, Yuen MF, Jeffers L, Sherman M, Min A, Mencarini K, Diva U, Cross A, Wilber R, Lopez-Talavera J.
    Hepatology; 2009 Jan 17; 49(1):72-9. PubMed ID: 19065670
    [Abstract] [Full Text] [Related]

  • 28. Entecavir versus lamivudine for hepatitis B prophylaxis in patients with haematological disease.
    Chen FW, Coyle L, Jones BE, Pattullo V.
    Liver Int; 2013 Sep 17; 33(8):1203-10. PubMed ID: 23522150
    [Abstract] [Full Text] [Related]

  • 29. The efficacy and safety of tacrolimus monotherapy in adult-onset nephrotic syndrome caused by idiopathic membranous nephropathy.
    Liang Q, Li H, Xie X, Qu F, Li X, Chen J.
    Ren Fail; 2017 Nov 17; 39(1):512-518. PubMed ID: 28562168
    [Abstract] [Full Text] [Related]

  • 30. Suppressive effects of entecavir on hepatitis B virus and hepatocellular carcinoma.
    Jin YJ, Shim JH, Lee HC, Yoo DJ, Kim KM, Lim YS, Suh DJ.
    J Gastroenterol Hepatol; 2011 Sep 17; 26(9):1380-8. PubMed ID: 21884247
    [Abstract] [Full Text] [Related]

  • 31. Retrospective analysis of tacrolimus combined with Tripterygium wilfordii polyglycoside for treating idiopathic membranous nephropathy.
    Shang SL, Cai GY, Duan SW, Li P, Li QG, Chen XM.
    BMC Nephrol; 2018 Jul 18; 19(1):182. PubMed ID: 30021637
    [Abstract] [Full Text] [Related]

  • 32. Efficacy of Prophylactic Entecavir for Hepatitis B Virus-Related Hepatocellular Carcinoma Receiving Transcatheter Arterial Chemoembolization.
    Li X, Zhong X, Chen ZH, Wang TT, Ma XK, Xing YF, Wu DH, Dong M, Chen J, Ruan DY, Lin ZX, Wen JY, Wei L, Wu XY, Lin Q.
    Asian Pac J Cancer Prev; 2015 Jul 18; 16(18):8665-70. PubMed ID: 26745134
    [Abstract] [Full Text] [Related]

  • 33. Successful Use of Entecavir in Hepatitis B-associated Membranous Nephropathy.
    Mahajan V, D'Cruz S, Nada R, Sachdev A.
    J Trop Pediatr; 2018 Jun 01; 64(3):249-252. PubMed ID: 28977667
    [Abstract] [Full Text] [Related]

  • 34. Efficacy and safety of entecavir in lamivudine-refractory patients with chronic hepatitis B: randomized controlled trial in Japanese patients.
    Suzuki F, Toyoda J, Katano Y, Sata M, Moriyama M, Imazeki F, Kage M, Seriu T, Omata M, Kumada H.
    J Gastroenterol Hepatol; 2008 Sep 01; 23(9):1320-6. PubMed ID: 18554238
    [Abstract] [Full Text] [Related]

  • 35. Comparison of entecavir monotherapy and de novo lamivudine and adefovir combination therapy in HBeAg-positive chronic hepatitis B with high viral load: 48-week result.
    Cai S, Yu T, Jiang Y, Zhang Y, Lv F, Peng J.
    Clin Exp Med; 2016 Aug 01; 16(3):429-36. PubMed ID: 26164128
    [Abstract] [Full Text] [Related]

  • 36. Relationship between virological response and FIB-4 index in chronic hepatitis B patients with entecavir therapy.
    Li N, Xu JH, Yu M, Wang S, Si CW, Yu YY.
    World J Gastroenterol; 2015 Nov 21; 21(43):12421-9. PubMed ID: 26604649
    [Abstract] [Full Text] [Related]

  • 37. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
    Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, Lok AS, Han KH, Goodman Z, Zhu J, Cross A, DeHertogh D, Wilber R, Colonno R, Apelian D, BEHoLD AI463022 Study Group.
    N Engl J Med; 2006 Mar 09; 354(10):1001-10. PubMed ID: 16525137
    [Abstract] [Full Text] [Related]

  • 38. [A randomized controlled trial on 240-week monotherapy with entecavir or adefovir in patients with chronic hepatitis B and cirrhosis].
    Lian J, Han T, Xiang H, Liu F, Lyu H, Gao Y, Wang F.
    Zhonghua Gan Zang Bing Za Zhi; 2015 Oct 09; 23(10):733-7. PubMed ID: 26573188
    [Abstract] [Full Text] [Related]

  • 39. Correlation between entecavir penetration in peripheral blood mononuclear cells and HBV DNA decay during treatment of HBeAg-negative chronic hepatitis B.
    De Nicolò A, Boglione L, Cusato J, Fatiguso G, Favata F, Allegra S, Cariti G, Di Perri G, D'Avolio A.
    Antivir Ther; 2018 Oct 09; 23(4):373-377. PubMed ID: 29168696
    [Abstract] [Full Text] [Related]

  • 40. A comparison of telbivudine and entecavir for chronic hepatitis B in real-world clinical practice.
    Tsai MC, Lee CM, Chiu KW, Hung CH, Tung WC, Chen CH, Tseng PL, Chang KC, Wang JH, Lu SN, Yen YH, Hu TH.
    J Antimicrob Chemother; 2012 Mar 09; 67(3):696-9. PubMed ID: 22174039
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.